Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment
Rapid improvements in cancer survival led to the realization that many modalities used to treat or control cancer may cause accelerated aging in cancer survivors. Clinically, “accelerated aging” phenotypes in cancer survivors include secondary cancers, frailty, chronic organ dysfunction, and cogniti...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/3/427 |
| _version_ | 1797408032318029824 |
|---|---|
| author | Shuo Wang Anna Prizment Bharat Thyagarajan Anne Blaes |
| author_facet | Shuo Wang Anna Prizment Bharat Thyagarajan Anne Blaes |
| author_sort | Shuo Wang |
| collection | DOAJ |
| description | Rapid improvements in cancer survival led to the realization that many modalities used to treat or control cancer may cause accelerated aging in cancer survivors. Clinically, “accelerated aging” phenotypes in cancer survivors include secondary cancers, frailty, chronic organ dysfunction, and cognitive impairment, all of which can impact long-term health and quality of life in cancer survivors. The treatment-induced accelerated aging in cancer survivors could be explained by telomere attrition, cellular senescence, stem cell exhaustion, DNA damage, and epigenetic alterations. Several aging clocks and biomarkers of aging have been proposed to be potentially useful in estimating biological age, which can provide specific information about how old an individual is biologically independent of chronological age. Measuring biological age in cancer survivors may be important for two reasons. First, it can better predict the risk of cancer treatment-related comorbidities than chronological age. Second, biological age may provide additional value in evaluating the effects of treatments and personalizing cancer therapies to maximize efficacy of treatment. A deeper understanding of treatment-induced accelerated aging in individuals with cancer may lead to novel strategies that reduce the accelerated aging and improve the quality of life in cancer survivors. |
| first_indexed | 2024-03-09T03:51:27Z |
| format | Article |
| id | doaj.art-6a65490f89b44be8832a93b8cb2f3cab |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T03:51:27Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6a65490f89b44be8832a93b8cb2f3cab2023-12-03T14:26:12ZengMDPI AGCancers2072-66942021-01-0113342710.3390/cancers13030427Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and AssessmentShuo Wang0Anna Prizment1Bharat Thyagarajan2Anne Blaes3Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USADivision of Hematology, Oncology and Transplantation, Medical School, University of Minnesota, Minneapolis, MN 55455, USAMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USADivision of Hematology, Oncology and Transplantation, Medical School, University of Minnesota, Minneapolis, MN 55455, USARapid improvements in cancer survival led to the realization that many modalities used to treat or control cancer may cause accelerated aging in cancer survivors. Clinically, “accelerated aging” phenotypes in cancer survivors include secondary cancers, frailty, chronic organ dysfunction, and cognitive impairment, all of which can impact long-term health and quality of life in cancer survivors. The treatment-induced accelerated aging in cancer survivors could be explained by telomere attrition, cellular senescence, stem cell exhaustion, DNA damage, and epigenetic alterations. Several aging clocks and biomarkers of aging have been proposed to be potentially useful in estimating biological age, which can provide specific information about how old an individual is biologically independent of chronological age. Measuring biological age in cancer survivors may be important for two reasons. First, it can better predict the risk of cancer treatment-related comorbidities than chronological age. Second, biological age may provide additional value in evaluating the effects of treatments and personalizing cancer therapies to maximize efficacy of treatment. A deeper understanding of treatment-induced accelerated aging in individuals with cancer may lead to novel strategies that reduce the accelerated aging and improve the quality of life in cancer survivors.https://www.mdpi.com/2072-6694/13/3/427accelerated agingcancer treatmentcellular senescence |
| spellingShingle | Shuo Wang Anna Prizment Bharat Thyagarajan Anne Blaes Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment Cancers accelerated aging cancer treatment cellular senescence |
| title | Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment |
| title_full | Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment |
| title_fullStr | Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment |
| title_full_unstemmed | Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment |
| title_short | Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment |
| title_sort | cancer treatment induced accelerated aging in cancer survivors biology and assessment |
| topic | accelerated aging cancer treatment cellular senescence |
| url | https://www.mdpi.com/2072-6694/13/3/427 |
| work_keys_str_mv | AT shuowang cancertreatmentinducedacceleratedagingincancersurvivorsbiologyandassessment AT annaprizment cancertreatmentinducedacceleratedagingincancersurvivorsbiologyandassessment AT bharatthyagarajan cancertreatmentinducedacceleratedagingincancersurvivorsbiologyandassessment AT anneblaes cancertreatmentinducedacceleratedagingincancersurvivorsbiologyandassessment |